132 related articles for article (PubMed ID: 35859732)
1. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.
Bella Á; Arrizabalaga L; Di Trani CA; Cirella A; Fernandez-Sendin M; Gomar C; Russo-Cabrera JS; Rodríguez I; González-Gomariz J; Alvarez M; Teijeira Á; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
Oncoimmunology; 2022; 11(1):2098657. PubMed ID: 35859732
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
[TBL] [Abstract][Full Text] [Related]
5. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
[TBL] [Abstract][Full Text] [Related]
6. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
7. Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.
Lu SC; Hansen MJ; Hemsath JR; Parrett BJ; Zell BN; Barry MA
Hum Gene Ther; 2022 Mar; 33(5-6):250-261. PubMed ID: 34731019
[TBL] [Abstract][Full Text] [Related]
8. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
9. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis.
Bella Á; Melero I; Berraondo P; Aranda F
Oncoimmunology; 2023; 12(1):2285106. PubMed ID: 38126032
[TBL] [Abstract][Full Text] [Related]
10. Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages.
Neckermann P; Mohr M; Billmeier M; Karlas A; Boilesen DR; Thirion C; Holst PJ; Jordan I; Sandig V; Asbach B; Wagner R
Front Immunol; 2024; 15():1338492. PubMed ID: 38380318
[TBL] [Abstract][Full Text] [Related]
11. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.
Bereta M; Bereta J; Park J; Medina F; Kwak H; Kaufman HL
Cancer Gene Ther; 2004 Dec; 11(12):808-18. PubMed ID: 15359290
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
[No Abstract] [Full Text] [Related]
14. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
[TBL] [Abstract][Full Text] [Related]
16. Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
Baur K; Brinkmann K; Schweneker M; Pätzold J; Meisinger-Henschel C; Hermann J; Steigerwald R; Chaplin P; Suter M; Hausmann J
J Virol; 2010 Sep; 84(17):8743-52. PubMed ID: 20538860
[TBL] [Abstract][Full Text] [Related]
17. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
19. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
20. OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs.
Yang N; Wang Y; Liu S; Tariq SB; Luna JM; Mazo G; Tan A; Zhang T; Wang J; Yan W; Choi J; Rossi A; Xiang JZ; Rice CM; Merghoub T; Wolchok JD; Deng L
J Exp Med; 2023 Aug; 220(8):. PubMed ID: 37145142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
